Abstract | BACKGROUND: Provoked vestibulodynia is difficult to treat. The beneficial effects of botulinum toxin A are being considered because of the muscular anomalies observed in this pathology. OBJECTIVE: METHODS: Patients aged between 18 and 60 years presenting with provoked vestibulodynia (according to the 2003 International Society for the Study of Vulvar Disease classification) received 50 U of botulinum toxin A bilaterally in the bulbospongiosus muscle under electromyographic monitoring. Pain was evaluated by a visual analogue scale (VAS), quality of life was evaluated by the Dermatology Life Quality Index and sexual function by the Female Sexual Function Index. RESULTS: Twenty patients received the injections. Sixteen patients presented with a muscular hyperactivity on electromyography. After 3 months, 80% of the patients improved in terms of pain. Mean ± SD VAS values significantly decreased from 8·37 ± 1·22 (range 4·5-10) to 2·57 ± 2·67 (0-9; P < 0·0001) at month 3 and to 3·90 ± 2·92 (0-9; P < 0·001) at month 6. Quality of life and sexual function improved significantly during the first 6 months (P < 0·0001). After 3 months, 13 patients (out of 18 for whom intercourse was not possible before the injections; 72%) were able to have sexual intercourse. CONCLUSION:
|
Authors | F Pelletier, B Parratte, S Penz, J-P Moreno, F Aubin, P Humbert |
Journal | The British journal of dermatology
(Br J Dermatol)
Vol. 164
Issue 3
Pg. 617-22
(Mar 2011)
ISSN: 1365-2133 [Electronic] England |
PMID | 21275944
(Publication Type: Journal Article)
|
Copyright | © 2011 The Authors. BJD © 2011 British Association of Dermatologists. |
Chemical References |
- Neuromuscular Agents
- Botulinum Toxins, Type A
|
Topics |
- Adult
- Botulinum Toxins, Type A
(therapeutic use)
- Female
- Humans
- Injections, Intramuscular
- Neuromuscular Agents
(therapeutic use)
- Pain Measurement
- Quality of Life
- Sexual Dysfunction, Physiological
(drug therapy)
- Vulvodynia
(drug therapy)
- Young Adult
|